Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 12, 2024

Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

Robert Gabbay, MD, PhD, discusses the early intervention at the asymptomatic stages of type 1 diabetes characterized by autoimmune antibodies and gradual blood sugar elevations.

Episodes in this series

Video 1 - "Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2"

EP. 1 Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

Video 2 - "Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3"

EP. 2 Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

Video 3 - "Identifying Risk to Enable Early Detection of Type 1 Diabetes "

EP. 3 Identifying Risk to Enable Early Detection of Type 1 Diabetes

Video 4 - "Challenges in Autoantibody Screening for Type 1 Diabetes"

EP. 4 Challenges in Autoantibody Screening for Type 1 Diabetes

Video 5 - "Strategies for Preventing Progression of Early-Stage Type 1 Diabetes"

EP. 5 Strategies for Preventing Progression of Early-Stage Type 1 Diabetes

Video 6 - "Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus"

EP. 6 Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus

Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"

EP. 7 Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Nitin Jain | Image Credit: UT MD Anderson

Phase 1 UCART22 Trial Shows Promising Activity in R/R B-Cell ALL: Nitin Jain, MD

ByBrooke McCormick,Nitin Jain, MD

June 18th 2026

FDA approval | Image Credit: Tada Images - stock.adobe.com

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

ByBrooke McCormick

June 18th 2026

Elizabeth Budde, MD, PhD, presented results at ASCO that highlight the superior PFS of an ADC-bispecific combination in second-line LBCL. | Image: City of Hope

SUNMO: ADC Plus Bispecific Yields Double PFS of Chemotherapy at 2 Years in R/R LBCL, With Lowest CRS Rate Seen

ByElla Hohmann, MS,Mary Caffrey

June 18th 2026

Experts featured in this series.

What It Takes to Make the Pathway: Clinical and Operational Criteria for Adding New Combinations in RRFL

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

Published: June 18th 2026 | Updated: June 11th 2026

Experts featured in this series.

From Data to Practice: Interpreting inMIND Trial Results and the Role of Tafasitamab in RRFL

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

Published: June 18th 2026 | Updated: June 11th 2026

Trending on AJMC

Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology

Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer

Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD

Orexin Agonist Shows Promise for Treating Narcolepsy, Hypersomnia: Richard Bogan, MD

Study Finds Flaw in Method for Key Oncology Value-Based Care Model